AstraZeneca, US6549022043

AstraZeneca stock holds firm as revenue and EPS beat estimates

Published on 08/29/2026 at 08:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock is steady after a July 27, 2026 earnings update showed $15.38 billion in quarterly revenue and $2.63 in EPS.

Flachbild-Draufsicht pharmazeutischer Laborartikel auf weißem Untergrund mit ungebrandeten Tabletten, Kapseln, Petrischalen, Pipetten und DNA-Illustrationen
AstraZeneca US6549022043 Flatlay mit pharmazeutischen Laborartikeln generischen Tabletten Petrischalen und DNA Modellen, Illustration mit AI erstellt.

AstraZeneca plc stock is anchored by a July 27, 2026 earnings update that showed $15.38 billion in quarterly revenue and $2.63 in adjusted EPS, while the market value stood at $255.18 billion on August 28, 2026.

Earnings stay the anchor

In the quarter ended June 30, 2026, revenue rose 6.4% year over year from $14.45 billion, and EPS topped the $2.50 estimate by $0.13. The same report showed a net margin of 17.02%, with return on equity at 31.45%.

Sell-side expectations still point to $10.21 in full-year EPS, which frames the next set of updates for investors watching the shares.

Market value and range

The stock traded in a $161.18 to $163.54 intraday range on August 28, 2026, against a 52-week span of $146.10 to $212.71. That keeps the name below its one-year high while the market cap remains above $255 billion.

AstraZeneca's valuation also sits alongside a debt-to-equity ratio of 0.47 and a quick ratio of 0.67 in the latest market snapshot, signaling a large-cap pharma profile that is still being judged on execution rather than multiple expansion.

What the product mix supports

The company's oncology and rare-disease portfolio remains central to the case, because those franchises carry the revenue base behind the July 2026 quarter and support the consensus view on full-year earnings.

That matters more than a single session's move. The shares were last quoted at $161.18 to $163.54 on August 28, 2026, with the market cap at $255.18 billion.

More on AstraZeneca plc

Company: AstraZeneca plc

ISIN: US6549022043

Ticker: AZN

Exchange: NYSE

Price (as of August 28, 2026): $161.18 to $163.54 USD

Market cap: $255.18 billion (as of August 28, 2026)

Sector / Industry: Health Care / Pharmaceuticals

Index membership: Nasdaq-100

AstraZeneca shares and the August 2026 view

AstraZeneca plc stock stays tied to a $255.18 billion market value, a $146.10 to $212.71 52-week range, and a July 27, 2026 quarter that delivered $15.38 billion in revenue and $2.63 in EPS.

Disclaimer...

en | US6549022043 | ASTRAZENECA | boerse | 70018405 | bgmi